<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39465249</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.</ArticleTitle><Pagination><StartPage>201</StartPage><MedlinePgn>201</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">201</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00999-6</ELocationID><Abstract><AbstractText>Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3031-7194</Identifier><AffiliationInfo><Affiliation>Emory Vaccine Center, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory National Primate Research Center, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6262-1190</Identifier><AffiliationInfo><Affiliation>Emory Vaccine Center, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory National Primate Research Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azeem</LastName><ForeName>Maryam I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nooka</LastName><ForeName>Ajay K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Madison</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0325-5477</Identifier><AffiliationInfo><Affiliation>Emory Vaccine Center, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory National Primate Research Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manalo</LastName><ForeName>Renee Julia</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Switchenko</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wali</LastName><ForeName>Bushra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Emory Vaccine Center, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory National Primate Research Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmeister</LastName><ForeName>Craig C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-4816-1607</Identifier><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Nisha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonial</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhodapkar</LastName><ForeName>Kavita M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-0587-4172</Identifier><AffiliationInfo><Affiliation>Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dhodapkar</LastName><ForeName>Madhav V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-8249-5988</Identifier><AffiliationInfo><Affiliation>Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia. madhav.v.dhodapkar@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winship Cancer Institute, Atlanta, Georgia. madhav.v.dhodapkar@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Suthar</LastName><ForeName>Mehul S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Emory Vaccine Center, Emory University, Atlanta, Georgia. msuthar@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory National Primate Research Center, Atlanta, Georgia. msuthar@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. msuthar@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>A.M. reports grants from NIH during the conduct of the study. J.L.K. reports grants from NIH during the conduct of the study and personal fees from AbbVie, BMS, Janssen, and Incyte outside the submitted work. S.L. reports personal fees from Amgen, grants and personal fees from Takeda, Janssen, and BMS, personal fees from Pfizer, Genentech, AbbVie, and Celgene outside the submitted work; and Board of Directors TG Therapeutics with stock. M.V.D. personal fees from Sanofi, BMS, and Lava Therapeutics outside the submitted work. M.S.S. reports grants and personal fees from Moderna and Ocugen outside the submitted work. No disclosures were reported by the other authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39465249</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00999-6</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00999-6</ArticleId><ArticleId IdType="pmc">PMC11514147</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Laracy, J. C., Kamboj, M. &amp; Vardhana, S. A. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr. Opin. Infect. Dis.35, 271–279 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9922441</ArticleId><ArticleId IdType="pubmed">35849516</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood136, 2881–2892 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerril-Gaitan, A. et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur. J. Cancer160, 243–260 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548030</ArticleId><ArticleId IdType="pubmed">34794855</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med.383, 2291–2293 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo, T. et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N. Engl. J. Med.383, 2586–2588 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722690</ArticleId><ArticleId IdType="pubmed">33259154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, C. Y. et al. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov.12, 62–73 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges, V. et al. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. mSphere6, e0024421 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386466</ArticleId><ArticleId IdType="pubmed">34319130</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary, M. C., Crain, C. R., Qiu, X., Hanage, W. &amp; Li, J. Z. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am.74, 237–245 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135388</ArticleId><ArticleId IdType="pubmed">33906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature592, 277–282 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Azeem, M. I. et al. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood Cancer Discov.4, 106–117 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975771</ArticleId><ArticleId IdType="pubmed">36511813</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, F. F. et al. A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG. J. Clin. Virol.146, 105050 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632860</ArticleId><ArticleId IdType="pubmed">34883405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, A. et al. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer Res Commun.2, 1684–1692 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833496</ArticleId><ArticleId IdType="pubmed">36644323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooka, A. K. et al. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. J. Clin. Oncol.40, 3057–3064 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462534</ArticleId><ArticleId IdType="pubmed">35259002</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science377, eabq1841 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleman, A. et al. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma. EBioMedicine98, 104886 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10708991</ArticleId><ArticleId IdType="pubmed">37995467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner, A. et al. Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants. Vaccines12, 10.3390/vaccines12050518 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11125692</ArticleId><ArticleId IdType="pubmed">38793769</ArticleId></ArticleIdList></Reference><Reference><Citation>Branagan, A. R. et al. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Adv.5, 1535–1539 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948269</ArticleId><ArticleId IdType="pubmed">33683337</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med.388, 183–185 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara, V. V. et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe29, 516–521 e513 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980225</ArticleId><ArticleId IdType="pubmed">33798491</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe27, 841–848 e843 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153529</ArticleId><ArticleId IdType="pubmed">32289263</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med.3, 100529 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784612</ArticleId><ArticleId IdType="pubmed">35233550</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med.385, 664–666 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279090</ArticleId><ArticleId IdType="pubmed">34233096</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden, A. et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. Curr. Protoc. Immunol.131, e116 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864545</ArticleId><ArticleId IdType="pubmed">33215858</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick, L. C. et al. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Negl. Trop. Dis.12, e0006862 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226209</ArticleId><ArticleId IdType="pubmed">30356267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>